{"id":49279,"date":"2024-12-17T16:44:49","date_gmt":"2024-12-17T11:14:49","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=49279"},"modified":"2025-04-09T14:52:09","modified_gmt":"2025-04-09T09:22:09","slug":"mankind-pharma-surges-3-9-after-3000-crore-qip","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/mankind-pharma-surges-3-9-after-3000-crore-qip\/","title":{"rendered":"Mankind Pharma Surges 3.9% as Company Launches Rs 3,000 Crore QIP"},"content":{"rendered":"
<\/div>\n

<\/p>\n\n\n\n

Mankind Pharma, a leading player in the Indian pharmaceutical space, recently made headlines by launching a Qualified Institutional Placement (QIP) worth Rs 3,000 crore. This move has not only brought Mankind Pharma’s shares into the limelight but also raised investors’ curiosity about its broader growth strategy. <\/p>\n\n\n\n

The QIP launch aims to fund the company’s acquisition of Bharat Serums and Vaccines, which could further solidify Mankind Pharma\u2019s position in the competitive pharmaceutical market.  Source: Economic Times<\/a><\/p>\n\n\n\n

\"\"
Source: <\/strong>Moneycontrol<\/strong><\/a><\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Let\u2019s break down the details, implications, and what this means for investors but first look at the key information of the QIP.<\/p>\n\n\n\n

Key Details of the QIP Launch<\/strong><\/h3>\n\n\n\n
Objective<\/strong><\/td>The funds will contribute to the Rs 13,630-crore deal for acquiring BSV<\/td><\/tr>
Floor Price<\/strong><\/td>Mankind Pharma can offer a discount of up to 5% on the floor price to qualified institutional buyers.<\/td><\/tr>
Discount Option<\/strong><\/td>Kotak Mahindra Capital and IIFL Capital are advisors for Mankind Pharma’s QIP. <\/td><\/tr>
Launch Date<\/strong><\/td>The QIP opened on December 16, 2024.<\/td><\/tr>
Advisors for the QIP<\/strong><\/td>Kotak Mahindra Capital and IIFL Capital are acting as advisors for Mankind Pharma’s QIP. <\/td><\/tr><\/tbody><\/table>
Source: <\/strong>Moneycontrol<\/strong><\/a><\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Before delving into the funding plan, look at Mankind Pharma\u2019s financial performance in the latest quarter.<\/p>\n\n\n\n

Financial Highlights<\/strong><\/h3>\n\n\n\n
Market Capitalization in Crore (as of 17.12.24)<\/strong><\/td>CMP (as of 17.12.24)<\/strong><\/td>PE Ratio<\/strong><\/td>ROCE<\/a> %<\/strong><\/td>1 Yr Return %<\/strong><\/td><\/tr>
\u20b9 1,06,554<\/td>\u20b9 2,659<\/td>53.2<\/td>24.6<\/td>39<\/td><\/tr><\/tbody><\/table>
Source: Screener<\/a><\/figcaption><\/figure>\n\n\n\n

For the quarter ending September 2024, the company reported a revenue of Rs 2,530 crore, reflecting a 12% increase compared to Rs 2,260 crore in the same quarter of the previous year. Additionally, the company\u2019s profit saw a significant growth of 34%, rising to Rs 634 crore from Rs 473 crore recorded in the corresponding quarter of the previous year. <\/p>\n\n\n\n

<\/p>\n\n\n\n

Financial Strength and Growth Prospects<\/strong><\/h2>\n\n\n\n

Mankind Pharma has demonstrated consistent financial performance over the years. With a strong focus on domestic markets, the company has reported steady revenue growth and healthy profit margins.<\/p>\n\n\n\n